Literature DB >> 2007517

[Progress in oral antibiotic therapy in practice].

H E Pichler1.   

Abstract

Any antibiotic agent that improves the safety of antibiotic treatment means progress in the management of infectious diseases. A new antibiotic has to show the following properties in order to signify progress compared to the well established antibiotics: Better antibacterial activity, better pharmacokinetic and pharmacodynamic properties, which improve patient compliance. Reduction of costs for antibiotic treatment also means progress. Infections most frequently seen in outpatients who are usually treated with oral antibiotics are respiratory and urinary tract infections. Progress in the management of infectious diseases by the introduction of quinolones, combination of amoxicillin-clavulanic acid, new macrolides and new oral cephalosporins is discussed.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2007517     DOI: 10.1007/bf01644737

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  10 in total

Review 1.  Treatment of Branhamella catarrhalis infections.

Authors:  B I Davies; F P Maesen
Journal:  J Antimicrob Chemother       Date:  1990-01       Impact factor: 5.790

2.  Drug resistance in Shigella dysenteriae, S flexneri and S boydii in England and Wales: increasing incidence of resistance to trimethoprim.

Authors:  R J Gross; E J Threlfall; L R Ward; B Rowe
Journal:  Br Med J (Clin Res Ed)       Date:  1984-03-10

Review 3.  Comparative pharmacokinetics of macrolides.

Authors:  O G Nilsen
Journal:  J Antimicrob Chemother       Date:  1987-11       Impact factor: 5.790

4.  Comparison of azithromycin and erythromycin in the treatment of atypical pneumonias.

Authors:  S Schönwald; M Gunjaca; L Kolacny-Babić; V Car; M Gosev
Journal:  J Antimicrob Chemother       Date:  1990-01       Impact factor: 5.790

5.  Comparative in-vitro activity of azithromycin and erythromycin against Gram-positive cocci, Haemophilus influenzae and anaerobes.

Authors:  J P Maskell; A M Sefton; J D Williams
Journal:  J Antimicrob Chemother       Date:  1990-01       Impact factor: 5.790

6.  Azithromycin in the treatment of sexually transmitted disease.

Authors:  O Steingrimsson; J H Olafsson; H Thorarinsson; R W Ryan; R B Johnson; R C Tilton
Journal:  J Antimicrob Chemother       Date:  1990-01       Impact factor: 5.790

7.  The pharmacokinetics of azithromycin in human serum and tissues.

Authors:  G Foulds; R M Shepard; R B Johnson
Journal:  J Antimicrob Chemother       Date:  1990-01       Impact factor: 5.790

8.  Clinical efficacy of ciprofloxacin compared with placebo in bacterial diarrhea.

Authors:  H E Pichler; G Diridl; K Stickler; D Wolf
Journal:  Am J Med       Date:  1987-04-27       Impact factor: 4.965

9.  Development of resistance to nalidixic acid and the fluoroquinolones after the introduction of norfloxacin and ofloxacin.

Authors:  M Kresken; B Wiedemann
Journal:  Antimicrob Agents Chemother       Date:  1988-08       Impact factor: 5.191

10.  National collaborative study of the prevalence of antimicrobial resistance among clinical isolates of Haemophilus influenzae.

Authors:  G V Doern; J H Jorgensen; C Thornsberry; D A Preston; T Tubert; J S Redding; L A Maher
Journal:  Antimicrob Agents Chemother       Date:  1988-02       Impact factor: 5.191

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.